[Hepatic involvement associated with ingestion of metapramine].
The authors report the cases of 3 women who developed hepatic injury during administration of metapramine, a tricyclic antidepressant introduced in France in 1984. One patient had jaundice and pruritus; the 2 others had loss of weight. Serum alkaline phosphatase and serum transaminase activities were increased in 3 and 2 patients, respectively. Blood hypereosinophilia was found in one patient; erythrocyte sedimentation rate was elevated in 2 patients. The outcome was favorable after drug withdrawal in the 3 patients. Liver biopsy showed centrolobular cholestasis in the 3 patients. There was no rechallenge; in 2 patients, other drugs than metapramine might be implicated in hepatic injury; however, the similarity of these 3 cases suggests that metapramine, like other tricyclic antidepressants, may be responsible for hepatic injury.
Barbare
J C
JC
Service d'Hépato-gastroentérologie, Centre Hospitalier, Compiègne.
Latrive
J P
JP
Kaloustian
E
E
Broquie
G
G
Legendre
C
C
Poupon
R
R
D000368:Aged; D000929:Antidepressive Agents, Tricyclic / Q000009:adverse effects*; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology*; D003984:Dibenzazepines / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008875:Middle Aged
D000929:Antidepressive Agents, Tricyclic; D003984:Dibenzazepines; C012677:metapramine
Atteinte hépatique associée à la prise de métapramine.